Tetanus  ||| S:0 E:8 ||| JJ
toxoid  ||| S:8 E:15 ||| JJ
IgE  ||| S:15 E:19 ||| NN
may  ||| S:19 E:23 ||| MD
be  ||| S:23 E:26 ||| VB
useful  ||| S:26 E:33 ||| JJ
in  ||| S:33 E:36 ||| IN
predicting  ||| S:36 E:47 ||| VBG
allergy  ||| S:47 E:55 ||| NN
during  ||| S:55 E:62 ||| IN
childhood  ||| S:62 E:72 ||| JJ
Hypersensitivity  ||| S:72 E:89 ||| JJ
reactions  ||| S:89 E:99 ||| NNS
after  ||| S:99 E:105 ||| IN
immunization  ||| S:105 E:118 ||| NN
with  ||| S:118 E:123 ||| IN
tetanus  ||| S:123 E:131 ||| JJ
toxoid  ||| S:131 E:138 ||| NNS
are  ||| S:138 E:142 ||| VBP
occasionally  ||| S:142 E:155 ||| RB
observed  ||| S:155 E:164 ||| VBN
in  ||| S:164 E:167 ||| IN
atopic  ||| S:167 E:174 ||| NN
and  ||| S:174 E:178 ||| CC
non-atopic  ||| S:178 E:189 ||| JJ
individuals ||| S:189 E:200 ||| NNS
.  ||| S:200 E:202 ||| .
High  ||| S:202 E:207 ||| JJ
IgE  ||| S:207 E:211 ||| JJ
levels  ||| S:211 E:218 ||| NNS
in  ||| S:218 E:221 ||| IN
infancy  ||| S:221 E:229 ||| NN
may  ||| S:229 E:233 ||| MD
predict  ||| S:233 E:241 ||| VB
subsequent  ||| S:241 E:252 ||| JJ
allergy ||| S:252 E:259 ||| NN
.  ||| S:259 E:261 ||| .
The  ||| S:261 E:265 ||| DT
aims  ||| S:265 E:270 ||| NNS
of  ||| S:270 E:273 ||| IN
this  ||| S:273 E:278 ||| DT
study  ||| S:278 E:284 ||| NN
were ||| S:284 E:288 ||| VBD
:  ||| S:288 E:290 ||| :
i ||| S:290 E:291 ||| FW
)  ||| S:291 E:293 ||| -RRB-
to  ||| S:293 E:296 ||| TO
evaluate  ||| S:296 E:305 ||| VB
the  ||| S:305 E:309 ||| DT
role  ||| S:309 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
specific  ||| S:317 E:326 ||| JJ
IgE  ||| S:326 E:330 ||| JJ
to  ||| S:330 E:333 ||| TO
tetanus  ||| S:333 E:341 ||| VB
toxoid  ||| S:341 E:348 ||| VBN
in  ||| S:348 E:351 ||| IN
children  ||| S:351 E:360 ||| NNS
in  ||| S:360 E:363 ||| IN
response  ||| S:363 E:372 ||| NN
to  ||| S:372 E:375 ||| TO
tetanus  ||| S:375 E:383 ||| VB
immunization  ||| S:383 E:396 ||| NNS
and  ||| S:396 E:400 ||| CC
the  ||| S:400 E:404 ||| DT
possible  ||| S:404 E:413 ||| JJ
factors  ||| S:413 E:421 ||| NNS
associated  ||| S:421 E:432 ||| VBN
with  ||| S:432 E:437 ||| IN
specific  ||| S:437 E:446 ||| JJ
IgE  ||| S:446 E:450 ||| JJ
levels ||| S:450 E:456 ||| NNS
,  ||| S:456 E:458 ||| ,
and  ||| S:458 E:462 ||| CC
ii ||| S:462 E:464 ||| CD
)  ||| S:464 E:466 ||| -RRB-
to  ||| S:466 E:469 ||| TO
investigate  ||| S:469 E:481 ||| VB
the  ||| S:481 E:485 ||| DT
correlation  ||| S:485 E:497 ||| NN
between  ||| S:497 E:505 ||| IN
specific  ||| S:505 E:514 ||| JJ
IgE  ||| S:514 E:518 ||| JJ
levels  ||| S:518 E:525 ||| NNS
to  ||| S:525 E:528 ||| TO
tetanus  ||| S:528 E:536 ||| VB
toxoid  ||| S:536 E:543 ||| NNS
and  ||| S:543 E:547 ||| CC
the  ||| S:547 E:551 ||| DT
late  ||| S:551 E:556 ||| JJ
development  ||| S:556 E:568 ||| NN
of  ||| S:568 E:571 ||| IN
allergy  ||| S:571 E:579 ||| NN
( ||| S:579 E:580 ||| -LRB-
up  ||| S:580 E:583 ||| RB
to  ||| S:583 E:586 ||| TO
12  ||| S:586 E:589 ||| CD
years ||| S:589 E:594 ||| NNS
) ||| S:594 E:595 ||| -RRB-
.  ||| S:595 E:597 ||| .
Initially ||| S:597 E:606 ||| RB
,  ||| S:606 E:608 ||| ,
278  ||| S:608 E:612 ||| CD
healthy  ||| S:612 E:620 ||| JJ
infants  ||| S:620 E:628 ||| NNS
( ||| S:628 E:629 ||| -LRB-
152  ||| S:629 E:633 ||| CD
males  ||| S:633 E:639 ||| NNS
and  ||| S:639 E:643 ||| CC
126  ||| S:643 E:647 ||| CD
females ||| S:647 E:654 ||| NNS
,  ||| S:654 E:656 ||| ,
aged  ||| S:656 E:661 ||| VBN
12  ||| S:661 E:664 ||| CD
months ||| S:664 E:670 ||| NNS
)  ||| S:670 E:672 ||| -RRB-
living  ||| S:672 E:679 ||| VBG
in  ||| S:679 E:682 ||| IN
an  ||| S:682 E:685 ||| DT
urban  ||| S:685 E:691 ||| JJ
city  ||| S:691 E:696 ||| NN
were  ||| S:696 E:701 ||| VBD
screened  ||| S:701 E:710 ||| VBN
for  ||| S:710 E:714 ||| IN
serum  ||| S:714 E:720 ||| JJ
total  ||| S:720 E:726 ||| JJ
IgE  ||| S:726 E:730 ||| JJ
and  ||| S:730 E:734 ||| CC
specific  ||| S:734 E:743 ||| JJ
IgE  ||| S:743 E:747 ||| JJ
to  ||| S:747 E:750 ||| TO
tetanus  ||| S:750 E:758 ||| VB
toxoid ||| S:758 E:764 ||| NNS
,  ||| S:764 E:766 ||| ,
after  ||| S:766 E:772 ||| IN
having  ||| S:772 E:779 ||| VBG
obtained  ||| S:779 E:788 ||| VBN
informed  ||| S:788 E:797 ||| VBN
consent  ||| S:797 E:805 ||| NN
from  ||| S:805 E:810 ||| IN
parents ||| S:810 E:817 ||| NNS
.  ||| S:817 E:819 ||| .
After  ||| S:819 E:825 ||| IN
12  ||| S:825 E:828 ||| CD
years ||| S:828 E:833 ||| NNS
,  ||| S:833 E:835 ||| ,
151  ||| S:835 E:839 ||| CD
children  ||| S:839 E:848 ||| NNS
could  ||| S:848 E:854 ||| MD
be  ||| S:854 E:857 ||| VB
evaluated ||| S:857 E:866 ||| VBN
.  ||| S:866 E:868 ||| .
Total  ||| S:868 E:874 ||| JJ
IgE  ||| S:874 E:878 ||| JJ
summed  ||| S:878 E:885 ||| NN
with  ||| S:885 E:890 ||| IN
tetanus  ||| S:890 E:898 ||| JJ
specific  ||| S:898 E:907 ||| JJ
IgE  ||| S:907 E:911 ||| NN
were  ||| S:911 E:916 ||| VBD
significantly  ||| S:916 E:930 ||| RB
associated  ||| S:930 E:941 ||| VBN
with  ||| S:941 E:946 ||| IN
allergy  ||| S:946 E:954 ||| NN
at  ||| S:954 E:957 ||| IN
12  ||| S:957 E:960 ||| CD
years ||| S:960 E:965 ||| NNS
.  ||| S:965 E:967 ||| .
In  ||| S:967 E:970 ||| IN
conclusion ||| S:970 E:980 ||| NN
,  ||| S:980 E:982 ||| ,
this  ||| S:982 E:987 ||| DT
study  ||| S:987 E:993 ||| NN
demonstrates  ||| S:993 E:1006 ||| VBZ
that  ||| S:1006 E:1011 ||| DT
serum  ||| S:1011 E:1017 ||| JJ
total  ||| S:1017 E:1023 ||| JJ
IgE  ||| S:1023 E:1027 ||| JJ
and  ||| S:1027 E:1031 ||| CC
tetanus  ||| S:1031 E:1039 ||| JJ
specific  ||| S:1039 E:1048 ||| JJ
IgE  ||| S:1048 E:1052 ||| NN
may  ||| S:1052 E:1056 ||| MD
be  ||| S:1056 E:1059 ||| VB
predictive  ||| S:1059 E:1070 ||| VBN
of  ||| S:1070 E:1073 ||| IN
subsequent  ||| S:1073 E:1084 ||| JJ
allergy  ||| S:1084 E:1092 ||| NN
onset ||| S:1092 E:1097 ||| NN
.  ||| S:1097 E:1099 ||| .
